Category Latin America/Caribbean

Brazil Issues Retaliation List Of US Products; IP-Protected Items In Next Round

Brazil has announced the list of 222 American products that could suffer retaliation with tariff rates of more than 100 percent of the value when imported to Brazil. The list could be followed by another including potentially hundreds of millions of dollars in non-tariff items related to intellectual property rights such as lower-priced patented pharmaceuticals.

Conférence de Copenhague: incertitude sur les droits de propriété intellectuelle

BARCELONE – Les négociations sur le climat se sont achevées le 6 novembre après une semaine de discussions. Malgré les assurances données par la plupart des délégations sur le fait que tout était possible lors de la Conférence de Copenhague sur le changement climatique qui aura lieu en décembre, l’incertitude demeure sur de nombreuses questions qui concernent notamment le financement, la réduction des émissions de gaz à effet de serre, le transfert de technologie et la nature de l’accord qui sera conclu à Copenhague.

Pour les experts, l’accès à des médicaments sûrs est une question de santé publique et non de propriété intellectuelle

Selon les participants à un récent événement organisé par Open Society Institute, les initiatives de lutte contre la contrefaçon pourraient limiter l’accès aux traitements sans pour autant réduire le problème des médicaments contrefaits, en particulier dans les pays en développement.

专家组:获取安全药品是公共卫生问题而非知识产权问题

在最近由开放社会协会(Open Society Institute)主办的一次会议上,与会专家表示,反假冒倡议可能阻碍人们获得药品,但无法解决假药问题,在发展中国家尤其如此。

Grupo de expertos considera que el acceso a los medicamentos seguros es una cuestión de salud pública y no de propiedad intelectual

Las iniciativas de lucha contra la falsificación podrían dificultar el acceso a los medicamentos sin que se logre paliar el problema de los fármacos falsificados, en particular en los países en desarrollo, según dijeron miembros de un grupo de expertos en un evento organizado recientemente por el Open Society Institute.

Access To Safe Medicine A Public Health Issue, Not IP, Says Panel

Anti-counterfeiting initiatives might have a negative impact on access to medicines while not addressing the problem of fake medicines, particularly in developing countries, according to panellists at a recent event organised by the Open Society Institute.

LDCs Commit To Use IP For Development At WIPO; Use Of Exceptions, Flexibilities Omitted

Officials from least developed nations on Friday agreed to a strategy for using intellectual property to encourage local innovation, protect national cultural and genetic resources, attract foreign direct investment, and spur development at a World Intellectual Property Organization forum on the use of intellectual property for “prosperity and development.” But they did not appear to highlight other options for development such as exceptions and limitations to copyright or flexibilities they are allowed in applying IP laws.

Innovation Policy Needs National Focus, Use Of TRIPS Obligations, Panellists Say

Innovation is a main driver for economic growth and development for developing countries, said speakers at an event focusing on innovation in Brazil, India and South Africa. But although innovation is increasing and is a priority in developing economies, one expert said invention capabilities remain in the hands of historical players and governments need to seek innovative policy responses.

ECOSOC Calls For Intensified Efforts On Public Health And Use Of TRIPS Flexibilities

The United Nations Economic and Social Council, a key coordinating body meeting this summer in Geneva, is considering ways to move nations faster toward global public health goals, with a warning from developing countries that intellectual property rights should not interfere with access to medical products and innovation.

Santa Cruz To Head Chilean IP Office; Kappos Named USPTO Director

A well-liked and influential IP policymaker in Geneva will head Chile’s national IP office, a US lawyer responsible for perhaps the world’s biggest industry patent portfolio will head the US IP office, and a fixture in the Geneva international trade negotiating and lobbying community is heading home to Canada.